Regeneron Pharmaceuticals (REGN) shares were down over 2% in recent Friday trading after multiple media reports said that a US appeals court denied the company's request to block sales of biosimilar versions of its drug Eylea.
The company was seeking to prevent Amgen (AMGN) and others from marketing copy-cat versions of its treatment for wet macular degeneration but the US Court of Appeals for the Federal Circuit upheld an earlier decision to deny Regeneron's motion for patent infringement.
The earlier motion was denied on grounds that the company could not prove Amgen infringed on Regeneron's patents covering a vial containing Eylea, according to reports.
Price: 664.59, Change: -16.02, Percent Change: -2.35
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。